Posted by Michael Wonder on 01 Dec 2016
Agenda for 7 December 2016 TC meeting
2 December 2016 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of aliskiren fumarate (Rasilez), ibrutinib (Imbruvica), nivolumab (Opdivo), aprotonin (Trasylol), alglucosidase alfa (Myozyme) and exzetimibe (Ezetrol).
